Ayala In Shadow Of SpringWorks In Rare Cancer Race
Israeli Biotech’s Stock Down Despite Desmoid Tumor Success
The companies’ respective gamma-secretase inhibitors provided positive data for desmoid tumors at the ESMO congress but SpringWork’s nirogacestat impressed the most.
You may also be interested in...
The Danish biotech is looking to end 2022 on a high after raising over $105m and posting positive Phase III data on glepaglutide.
The Swedish biotech is well positioned with soon-to-be late-stage clinical assets, commercial validation and a strong pipeline, new CEO Richard Godfrey tells Scrip.
Having led $30bn of acquisitions of companies at Sanofi, the new challenge for its former global head of partnering is to help make Owkin, “the most disruptive AI biotech company in the world,” he tells Scrip.